Women's Health Initiative (WHI)

This study has been completed.
Sponsor:
Collaborators:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Cancer Institute (NCI)
National Institute on Aging (NIA)
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00000611
First received: October 27, 1999
Last updated: November 24, 2015
Last verified: January 2006
  Purpose
To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).

Condition Intervention Phase
Bone Diseases
Breast Neoplasms
Cardiovascular Diseases
Colonic Neoplasms
Coronary Disease
Heart Diseases
Myocardial Ischemia
Osteoporosis
Postmenopause
Drug: hormone replacement therapy
Drug: estrogens
Drug: progestins
Drug: estrogen replacement therapy
Behavioral: diet, fat-restricted
Drug: calcium
Drug: vitamin D
Behavioral: dietary supplements
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Primary Completion Date: March 2005 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   50 Years to 79 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria
Postmenopausal women ages 50 to 79.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000611

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Cancer Institute (NCI)
National Institute on Aging (NIA)
Investigators
Investigator: Ross Prentice Fred Hutchinson Cancer Research Center
  More Information

Additional Information:
Publications:
Women's Health Initiative Steering Committee: Effects of Conjugated Equine Estrogen in Postmenopausal Women Having Undergone Hysterectomy: The Women's Health Initiative Randomized, Controlled Trials. Obstet Gynecol Surv, 59(8):599-600, 2004.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00000611     History of Changes
Other Study ID Numbers: 114 
Study First Received: October 27, 1999
Last Updated: November 24, 2015
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Bone Diseases
Breast Neoplasms
Cardiovascular Diseases
Colonic Neoplasms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Neoplasms
Arterial Occlusive Diseases
Arteriosclerosis
Breast Diseases
Colonic Diseases
Colorectal Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Heart Diseases
Intestinal Diseases
Intestinal Neoplasms
Musculoskeletal Diseases
Neoplasms by Site
Skin Diseases
Vascular Diseases
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on February 04, 2016